# Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

> **NCT00604968** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Caelyx (pegylated liposomal doxorubicin; SCH 200746)

## Key facts

- **NCT ID:** NCT00604968
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02-07
- **Primary completion:** 2009-10-16
- **Final completion:** 2009-10-16
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604968, "Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00604968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*